{"name":"Azienda Ospedaliera V. Cervello","slug":"azienda-ospedaliera-v-cervello","ticker":"","exchange":"","domain":"","description":"Azienda Ospedaliera V. Cervello is a specialized healthcare institution focused on providing advanced medical care and conducting clinical research in various therapeutic areas. The organization is known for its contributions to the treatment of chronic diseases, particularly in the areas of hematology and infectious diseases.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Deferiprone (DFP)","genericName":"Deferiprone (DFP)","slug":"deferiprone-dfp","indication":"Iron overload in patients with thalassemia major","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin","genericName":"PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin","slug":"peg-ifn-alpha2a-or-peg-ifn-alpha2b-and-ribavirin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Deferiprone (DFP)","genericName":"Deferiprone (DFP)","slug":"deferiprone-dfp","phase":"marketed","mechanism":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage.","indications":["Iron overload in patients with thalassemia major","Iron overload in other chronic transfusion-dependent anemias"],"catalyst":""},{"name":"PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin","genericName":"PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin","slug":"peg-ifn-alpha2a-or-peg-ifn-alpha2b-and-ribavirin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}